Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low molecular weight heparin for hypertriglyceridemic acute pancreatitis
ChiCTR2400082276Phase 4Not yet recruiting
- Sponsor
- Civil Aviation General Hospital
- Start
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of low molecular weight heparin calcium in acute pancreatitis (AP) and hypertriglyceridemia (3 arms), sponsored by Civil Aviation General Hospital. Primary endpoint: Organ failure. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
low molecular weight heparin calcium
03
Conditions
acute pancreatitis (AP)hypertriglyceridemia
Beyond the preview
Go deeper on ChiCTR2400082276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082276.